These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21366638)

  • 41. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
    Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J; Bendtzen K
    Ugeskr Laeger; 2010 Jan; 172(1):44-7. PubMed ID: 20056095
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New therapeutic approach in inflammatory bowel disease.
    Papa A; Mocci G; Scaldaferri F; Bonizzi M; Felice C; Andrisani G; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2009 Mar; 13 Suppl 1():33-5. PubMed ID: 19530509
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Effect of Maternal Peripartum Anti-TNFα Use on Infant Immune Response.
    Sheibani S; Cohen R; Kane S; Dubinsky M; Church JA; Mahadevan U
    Dig Dis Sci; 2016 Jun; 61(6):1622-7. PubMed ID: 26725061
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug therapy for inflammatory bowel disease in pregnancy and the puerperium.
    Moffatt DC; Bernstein CN
    Best Pract Res Clin Gastroenterol; 2007; 21(5):835-47. PubMed ID: 17889811
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
    Danese S; Angelucci E
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S217-27. PubMed ID: 20117345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Pregnancy and inflammatory bowel disease: experience in 17 patients].
    Vergara A MT; Rey G P
    Rev Med Chil; 2011 Nov; 139(11):1421-7. PubMed ID: 22446646
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preconceptional Counselling of IBD Patients.
    van der Woude CJ; Kanis SL
    J Crohns Colitis; 2016 Aug; 10(8):871-2. PubMed ID: 27208387
    [No Abstract]   [Full Text] [Related]  

  • 48. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn.
    Vasiliauskas EA; Church JA; Silverman N; Barry M; Targan SR; Dubinsky MC
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1255-8. PubMed ID: 17045211
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Infliximab use in children and adolescents with inflammatory bowel disease.
    de Ridder L; Benninga MA; Taminiau JA; Hommes DW; van Deventer SJ
    J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):3-14. PubMed ID: 17592358
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is safety infliximb during pregnancy in patients with inflammatory bowel disease?
    Argüelles-Arias F; Castro-Laria L; Barreiro-de Acosta M; García-Sánchez MV; Guerrero-Jiménez P; Gómez-García MR; Cordero-Ruiz P; Iglesias-Flores E; Gómez-Camacho F; Domínguez-Muñoz EJ; Herrerías-Gutiérrez JM
    Rev Esp Enferm Dig; 2012 Feb; 104(2):59-64. PubMed ID: 22372798
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Anti-TNFα therapy and its implication in gynecology and obstetrics].
    Ducarme G; Amate P; Seirafi M; Ceccaldi PF; Bouhnik Y; Luton D
    J Gynecol Obstet Biol Reprod (Paris); 2011 Oct; 40(6):492-7. PubMed ID: 21733638
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery.
    Kane S; Ford J; Cohen R; Wagner C
    J Clin Gastroenterol; 2009 Aug; 43(7):613-6. PubMed ID: 19142167
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Optimizing effect of infliximab upon inflammatory bowel disease].
    Li SR; Sheng JQ; Li SJ; Zhao XJ
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2568-70. PubMed ID: 20137621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Inflammatory bowel disease and possible applications of tumor necrosis factor inhibitors in pregnant women].
    Li ED
    Eksp Klin Gastroenterol; 2013; (3):58-62. PubMed ID: 24294773
    [No Abstract]   [Full Text] [Related]  

  • 56. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
    Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Editorial: Are thiopurines and anti-TNFα agents safe to use in pregnant patients with inflammatory bowel disease?
    Sheibani S; Mahadevan U
    Am J Gastroenterol; 2013 Mar; 108(3):441-3. PubMed ID: 23459048
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions.
    Leung Y; Panaccione R; Ghosh S; Seow CH
    Can J Gastroenterol Hepatol; 2014 Oct; 28(9):505-9. PubMed ID: 25101334
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-tumor necrosis factor therapy for pediatric inflammatory bowel diseases.
    Bujanover Y; Weiss B
    Isr Med Assoc J; 2008; 10(8-9):634-9. PubMed ID: 18847168
    [No Abstract]   [Full Text] [Related]  

  • 60. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
    Rosner I; Haddad A; Boulman N; Feld J; Avshovich N; Slobodin G; Rozenbaum M
    Rheumatology (Oxford); 2007 Sep; 46(9):1508; author reply 1508-9. PubMed ID: 17684027
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.